<DOC>
	<DOC>NCT02267213</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of TLC388 (Lipotecan) as a second line treatment in subjects with advanced Hepatocellular Carcinoma.</brief_summary>
	<brief_title>Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>Radiological diagnosis of hepatic tumor(s) by contrastenhanced study Subjects with advanced HCC who are not eligible for surgical resection or locoregional therapy. Subjects with sorafenib treatment failure due to sorafenib intolerance or radiographic PD (as per RECIST v1.1). Prior sorafenib use should be ≥ 400 mg/day for at least 14 days. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 Child Pugh Score ≤ 6; A life expectancy of at least 12 weeks or more Subjects who have received any systemic target therapy or systemic chemotherapy other than sorafenib for the treatment of HCC. Subjects who have received sorafenib within 2 weeks prior to the initiation of the treatment dose, or have any sorafenibrelated toxicities not yet resolved to grade 1 or baseline. Subjects who have undergone liver transplantation surgery. Major surgery within 4 weeks prior to the initiation of the treatment dose (excluding implantation of the intravenous infusion device). Percutaneous liver puncture within 2 weeks prior to the initiation of the treatment dose.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>